Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Roger Pomerantz
AddedMar 31, 2024
UpdatedMay 31, 2026
Roger Pomerantz

Roger Pomerantz

Board Member, Viracta Therapeutics

CrunchbaseLinkedIn

Roger Pomerantz's Career

Viracta Therapeutics
Viracta Therapeutics

Cardiff-by-the-Sea, CA, US

Board Member· Board
Seres Therapeutics
Seres Therapeutics

Cambridge, MA, US

Board Member· Board
X-Vax Technology
X-Vax Technology

Jupiter, FL, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Roger Pomerantz's Career

Viracta Therapeutics
Viracta Therapeutics
Public$194.9M512007Cardiff-by-the-Sea, CA, US
Board Member· Board

Leadership at Viracta Therapeutics

Ronald BerensonRonald BerensonCo-Founder
Thomas E. DarcyThomas E. DarcyBoard Member
Barry SimonBarry SimonBoard Member
Ivor RoystonIvor RoystonBoard Member
George HillmanGeorge HillmanCo-Founder
Stephen RubinoStephen RubinoBoard Member
Seres Therapeutics
Seres Therapeutics
Public$537.8M4312010Cambridge, MA, US
Board Member· Board

Leadership at Seres Therapeutics

Noubar AfeyanNoubar AfeyanCo-Founder
David BerryDavid BerryCo-Founder
Willard DereWillard DereBoard Member
Meryl ZausnerMeryl ZausnerBoard Member
Paul BiondiPaul BiondiBoard Member
Greg BeharGreg BeharBoard Member

Similar to Seres Therapeutics

Microbiome TherapeuticsMicrobiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30
Solarea BioSolarea BioCambridge, MA, USBiotechnology, Therapeuticsest. 2017Solarea BioCambridge, MA, US · est. 2017

Solarea Bio, a Cambridge-based biotech firm, innovates microbiome solutions for global health issues.

Series B · $26.2M24
DermBiontDermBiontBoston, MA, USTherapeuticsest. 2017DermBiontBoston, MA, US · est. 2017

DermBiont: A leading precision dermatology firm, developing targeted therapeutics for skin health.

Series B · $108.5M47
X-Vax Technology
X-Vax Technology
Series A$56M392015Jupiter, FL, US
Board Member· Board

Leadership at X-Vax Technology

Ulf WiinbergUlf WiinbergCEO
Isaac BlechIsaac BlechBoard Member

Roger Pomerantz's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Roger Pomerantz

Fred DotzlerFred DotzlerBoard Member · Bayhill TherapeuticsDavid PerryDavid PerryCo-Founder · NexprisePeter DorsmanPeter DorsmanBoard Member · Ideal IndustriesRichard A BaraschRichard A BaraschBoard Member · The Oncology InstituteDouglas FallerDouglas FallerBoard Member · Viracta TherapeuticsReinhard AmbrosReinhard AmbrosBoard Member · TruDataRx